GJB2 and prostate carcinoma: Cx32 potentiates the cytotoxicity of vinblastine and Src inhibitors in renal cell carcinoma cells [131], whereas Cx26 increases the effect of cisplatin in human bladder cancer cells [132] and of doxorubicin in prostate cancer cells [133].